Product Portfolio AiPing Pharmaceutical specializes in a broad range of generic prescription and OTC products including tablets, capsules, and soft gels, presenting multiple entry points for expanding product distribution and licensing opportunities.

Recent Asset Sale The company's sale of U.S. drug assets to Shandong Xinhua Pharma in 2018 suggests potential for collaboration on existing drug applications and distribution rights, opening avenues for partnership or licensing deals.

Market Focus Operating primarily in the generic pharmaceutical sector with a dedicated focus on product redevelopment and commercialization, AiPing offers an opportunity to target healthcare providers or distributors seeking cost-effective generic solutions.

Financial Scope With revenue estimated between $1 million and $10 million, AiPing represents a mid-sized company with growth potential, making it suitable for strategic partnerships aimed at scaling or entering new markets.

Global Operations Although based in the U.S., AiPing's involvement in international asset sales and its global operations point to possible expansion opportunities into emerging markets or collaboration around cross-border distribution channels.